Trial Profile
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination With Bempegaldesleukin (NKTR-214) With or Without Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 10 Mar 2023
Price :
$35
*
At a glance
- Drugs Bempegaldesleukin (Primary) ; Nivolumab (Primary) ; NKTR-262 (Primary)
- Indications Advanced breast cancer; Carcinoma; Colorectal cancer; Head and neck cancer; Malignant melanoma; Merkel cell carcinoma; Ovarian cancer; Renal cell carcinoma; Sarcoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms REVEAL
- Sponsors Nektar Therapeutics
- 24 Jun 2022 Status changed from active, no longer recruiting to discontinued.
- 12 Nov 2021 Results published in the Media Release
- 29 Oct 2021 Planned End Date changed from 1 Dec 2021 to 1 Oct 2022.